Carlton Hofferkamp & Jenks Wealth Management LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 1.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 61,425 shares of the biopharmaceutical company’s stock after purchasing an additional 856 shares during the quarter. Pfizer makes up 1.4% of Carlton Hofferkamp & Jenks Wealth Management LLC’s portfolio, making the stock its 18th biggest holding. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Pfizer were worth $2,198,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Signet Financial Management LLC increased its stake in Pfizer by 0.4% in the fourth quarter. Signet Financial Management LLC now owns 71,686 shares of the biopharmaceutical company’s stock valued at $3,129,000 after purchasing an additional 292 shares during the last quarter. Semmax Financial Advisors Inc. bought a new position in Pfizer during the 4th quarter valued at $585,000. Nomura Holdings Inc. boosted its stake in Pfizer by 1,854.2% during the 4th quarter. Nomura Holdings Inc. now owns 529,323 shares of the biopharmaceutical company’s stock valued at $22,956,000 after purchasing an additional 502,237 shares in the last quarter. LMR Partners LLP bought a new position in Pfizer during the 4th quarter valued at $2,920,000. Finally, IHT Wealth Management LLC boosted its stake in Pfizer by 42.3% during the 4th quarter. IHT Wealth Management LLC now owns 48,934 shares of the biopharmaceutical company’s stock valued at $2,136,000 after purchasing an additional 14,554 shares in the last quarter. Institutional investors own 71.69% of the company’s stock.
PFE has been the subject of a number of research reports. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research note on Tuesday, October 1st. Goldman Sachs Group reaffirmed a “buy” rating and set a $49.00 price target on shares of Pfizer in a research note on Monday, June 17th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Morgan Stanley decreased their price target on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 27th. Twelve investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $45.20.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.05. The business had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company’s revenue was down 1.5% compared to the same quarter last year. During the same period last year, the company posted $0.77 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.81 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 annualized dividend and a dividend yield of 3.97%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
In other Pfizer news, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, with a total value of $900,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott Gottlieb bought 3,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Why does a company issue an IPO?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.